Microbial Metabolites Are Involved in Tumorigenesis and Development by Regulating Immune Responses

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jan 3

PMID 38169949

Authors

Jiahui Liu

Ruxian Tian

Caiyu Sun

Ying Guo

Lei Dong

Yumei Li

Xicheng Song

Affiliations

Soon will be listed here.

Abstract

The human microbiota is symbiotic with the host and can create a variety of metabolites. Under normal conditions, microbial metabolites can regulate host immune function and eliminate abnormal cells in a timely manner. However, when metabolite production is abnormal, the host immune system might be unable to identify and get rid of tumor cells at the early stage of carcinogenesis, which results in tumor development. The mechanisms by which intestinal microbial metabolites, including short-chain fatty acids (SCFAs), microbial tryptophan catabolites (MTCs), polyamines (PAs), hydrogen sulfide, and secondary bile acids, are involved in tumorigenesis and development by regulating immune responses are summarized in this review. SCFAs and MTCs can prevent cancer by altering the expression of enzymes and epigenetic modifications in both immune cells and intestinal epithelial cells. MTCs can also stimulate immune cell receptors to inhibit the growth and metastasis of the host cancer. SCFAs, MTCs, bacterial hydrogen sulfide and secondary bile acids can control mucosal immunity to influence the occurrence and growth of tumors. Additionally, SCFAs, MTCs, PAs and bacterial hydrogen sulfide can also affect the anti-tumor immune response in tumor therapy by regulating the function of immune cells. Microbial metabolites have a good application prospect in the clinical diagnosis and treatment of tumors, and our review provides a good basis for related research.

Citing Articles

Design and synthesis of phenylthiophosphoryl dichloride derivatives and evaluation of their antitumour and anti-inflammatory activities.

Xu C, Yang N, Yu H, Wang X Front Chem. 2025; 12:1529211.

PMID: 39906126 PMC: 11790660. DOI: 10.3389/fchem.2024.1529211.

Microbial molecules, metabolites, and malignancy.

Thomas R Neoplasia. 2025; 60:101128.

PMID: 39827500 PMC: 11787689. DOI: 10.1016/j.neo.2025.101128.

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.

PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.

From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy.

Dora D, Szocs E, Soos A, Halasy V, Somodi C, Mihucz A Front Immunol. 2024; 15:1434804.

PMID: 39301033 PMC: 11410641. DOI: 10.3389/fimmu.2024.1434804.

References

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

Yang W, Yu T, Huang X, Bilotta A, Xu L, Lu Y . Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020; 11(1):4457. PMC: 7478978. DOI: 10.1038/s41467-020-18262-6. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Chen Y, Tsai W, Wu H, Chen C, Yeh W, Chen Y . Probiotic spp. act Against -induced Inflammation. J Clin Med. 2019; 8(1). PMC: 6352136. DOI: 10.3390/jcm8010090. View

Peterson L, Artis D . Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014; 14(3):141-53. DOI: 10.1038/nri3608. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Ye C, Geng Z, Dominguez D, Chen S, Fan J, Qin L . Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol. 2015; 196(2):915-23. PMC: 4707077. DOI: 10.4049/jimmunol.1500729. View

Shen X, Carlstrom M, Borniquel S, Jadert C, Kevil C, Lundberg J . Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic Biol Med. 2013; 60:195-200. PMC: 4077044. DOI: 10.1016/j.freeradbiomed.2013.02.024. View

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

10.

Ji M, Xu X, Xu Q, Hsiao Y, Martin C, Ukraintseva S . Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota. Nat Metab. 2023; 5(9):1526-1543. PMC: 10513933. DOI: 10.1038/s42255-023-00854-3. View

11.

Mizoguchi A . Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis. 2012; 18(9):1777-84. PMC: 3366176. DOI: 10.1002/ibd.22929. View

12.

Hashimoto M, Kamphorst A, Im S, Kissick H, Pillai R, Ramalingam S . CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annu Rev Med. 2018; 69:301-318. DOI: 10.1146/annurev-med-012017-043208. View

13.

Origanti S, Shantz L . Ras transformation of RIE-1 cells activates cap-independent translation of ornithine decarboxylase: regulation by the Raf/MEK/ERK and phosphatidylinositol 3-kinase pathways. Cancer Res. 2007; 67(10):4834-42. DOI: 10.1158/0008-5472.CAN-06-4627. View

14.

Duncan S, Conti E, Ricci L, Walker A . Links between Diet, Intestinal Anaerobes, Microbial Metabolites and Health. Biomedicines. 2023; 11(5). PMC: 10216541. DOI: 10.3390/biomedicines11051338. View

15.

Christl S, Eisner H, Dusel G, Kasper H, Scheppach W . Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis. Dig Dis Sci. 1996; 41(12):2477-81. DOI: 10.1007/BF02100146. View

16.

Chang P, Hao L, Offermanns S, Medzhitov R . The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014; 111(6):2247-52. PMC: 3926023. DOI: 10.1073/pnas.1322269111. View

17.

Srivastava S, Salter A, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K . Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 2019; 35(3):489-503.e8. PMC: 6450658. DOI: 10.1016/j.ccell.2019.02.003. View

18.

Liu H, Shen Z, Wang Z, Wang X, Zhang H, Qin J . Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci Rep. 2016; 6:21319. PMC: 4758033. DOI: 10.1038/srep21319. View

19.

Feng S, Cao Z, Wang X . Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta. 2013; 1836(2):197-210. DOI: 10.1016/j.bbcan.2013.05.001. View

20.

Cerf-Bensussan N, Gaboriau-Routhiau V . The immune system and the gut microbiota: friends or foes?. Nat Rev Immunol. 2010; 10(10):735-44. DOI: 10.1038/nri2850. View